Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 28 (TRAJ28) is a joining (J) gene segment of the T cell receptor (TCR) alpha locus, involved in the assembly of the variable region of the TCR alpha chain during T cell development. The TCR is a heterodimer consisting of alpha and beta (or gamma and delta) chains that recognizes antigen peptides presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells. TRAJ28 encodes only a short segment of the variable region and must recombine with a variable (V) segment to form a functional TCR alpha chain. This process contributes to the diversity of antigen recognition by T cells, a key aspect of adaptive immunity[1][3][4]. TRAJ28 by itself is not a receptor or drug target, but an essential component of the genomic organization enabling T cell receptor diversity through V(D)J recombination during T cell development[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 28 (TRAJ28).